Silva Pharmaceuticals Ltd.
DDSE:SILVAPHL9.50
BDT
0.00
(0.00%)
ISIN
BD0493SPL001
Return %
Stock
S&P 500
1Y
-1.04
14.20
3Y
-56.02
81.12
5Y
-56.62
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Mohammad Enayet Ullah
- Full Time Employees
- 615
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Dhaka Bangladesh
- IPO Date
- Oct 10, 2018
- Website
- silvapharma.com
- Similar Companies
- Business
- Silva Pharmaceuticals Limited is a Bangladesh-based pharmaceutical company engaged in the manufacturing, marketing, and distribution of finished generic pharmaceutical formulations and healthcare products. Founded in 2001 and headquartered in Dhaka, Bangladesh, the company operates a dedicated cGMP-compliant manufacturing facility located in Maijdee Court, Noakhali. Silva Pharmaceuticals produces a diversified portfolio of allopathic medicines across numerous therapeutic segments and dosage forms, supplying retail pharmacies, hospitals, clinics, and institutional healthcare providers throughout Bangladesh. The company's core product offerings comprise multiple finished dosage forms, including immediate-release, film-coated, and enteric-coated tablets; hard gelatin capsules; oral liquid syrups, solutions, and suspensions; dry powders for oral suspension reconstitution; and topical creams and ointments. Its principal therapeutic categories encompass antibacterial, antibiotic, and antifungal agents; analgesics, antipyretics, and non-steroidal anti-inflammatory drugs (NSAIDs); gastrointestinal treatments, including proton pump inhibitors, antacids, and antiulcerants; antihistamines, antiallergics, and respiratory formulations; cardiovascular and antihypertensive agents; oral antidiabetics; central nervous system (CNS) medications; and nutritional supplements, including multivitamins, minerals, and hematinics. The company commercializes its portfolio under established proprietary brand lines such as Silvacef, Silvaclav, Silvazith, Silvatil, Silpan, Silprex, Silvor, and Silvit. In recent developments, Silva Pharmaceuticals has undertaken balancing, modernization, rehabilitation, and expansion (BMRE) initiatives across its Noakhali manufacturing plant to scale up solid dosage and liquid production capacities, optimize manufacturing efficiency, and align cleanroom and HVAC infrastructures with current Good Manufacturing Practices (cGMP) and World Health Organization (WHO) standards. The company has continued to broaden its commercial catalog through line extensions and new product launches focused on high-demand therapeutic areas such as chronic cardiovascular therapies and diabetes management. Furthermore, Silva Pharmaceuticals has upgraded its quality assurance and analytical testing laboratories, expanded its nationwide distribution and sales network across all administrative divisions of Bangladesh, and advanced strategic regulatory initiatives to explore pharmaceutical export opportunities in emerging international markets.